EORTC Quality of Life Questionnaire QLQ-C30

Abstract

The EORTC Quality of Life Questionnaire QLQ-C30 is a standardized, modular instrument developed by the European Organisation for Research and Treatment of Cancer (EORTC) to assess the health-related quality of life (HRQoL) of cancer patients participating in international clinical trials. It is one of the most widely used and validated tools in oncology research globally. The questionnaire comprises 30 items designed to measure various functional dimensions, key symptoms commonly experienced by cancer patients, and global health status/QoL. Its robust structure allows for the attachment of specific disease or treatment modules, ensuring comprehensive and targeted HRQoL assessment.

Keywords

EORTC QLQ-C30, Quality of Life, Health-Related Quality of Life, Oncology, Cancer, Clinical Trials, Functional Scales, Symptom Scales, Psychometrics

Authors

N.K. Aaronson, M. Bullinger, S.A. Ahmedzai, K. Bjordal, P.M. Fayers, A. Cull

Purpose

The primary purpose of the EORTC QLQ-C30 is to provide a standardized, cross-culturally validated measure of the quality of life of patients with cancer. It was specifically designed for use in multinational clinical trials to evaluate the impact of different cancer treatments (such as chemotherapy, radiotherapy, or surgery) on a patient’s well-being beyond simple survival rates.

The instrument is intended to capture subjective patient experiences related to disease symptoms and treatment side effects. By providing scores across multiple domains, it allows researchers and clinicians to obtain a detailed profile of patient status, helping to inform comparative effectiveness research and supportive care decisions in the field of oncology.

Construct

The QLQ-C30 measures the construct of Health-Related Quality of Life (HRQoL), which encompasses the patient’s subjective evaluation of the impact of illness and treatment on their physical, psychological, and social functioning. The scale is structured around three main conceptual areas:

• Functional Scales (measuring physical, role, emotional, cognitive, and social functioning).
• Symptom Scales (measuring disease- and treatment-related distress, such as fatigue, pain, and nausea/vomiting).
• Global Health Status/QoL Scale (measuring overall perception of health and quality of life).

The scale utilizes a modular approach, where the core 30 items (C30) can be supplemented by specialized modules (e.g., specific cancer types like lung or breast) to capture unique, disease-specific HRQoL issues, thereby ensuring both breadth (core items) and depth (module items) in measurement.

Validity

The QLQ-C30 demonstrates extensive evidence of validity across diverse international populations and cancer diagnoses. Content validity was ensured through rigorous item selection based on patient and professional input across multiple European countries. Construct validity is supported by the clear separation of the functional and symptom scales as confirmed by its scoring structure, and its ability to differentiate between groups of patients with varying clinical statuses.

Furthermore, the instrument exhibits strong cross-cultural validity, having been translated and validated into over 100 languages. Studies, such as the Iranian validation study, confirm its applicability and meaningfulness in non-Western populations, indicating that the scales accurately measure the intended HRQoL concepts independent of linguistic or cultural differences.

Reliability

The psychometric properties of the QLQ-C30 are generally strong, particularly for the multi-item scales. Reliability is typically assessed using Cronbach’s alpha, with acceptable values generally ranging above 0.70 for group comparisons. The reported alpha ranges from the source content are:

• Global Health/QoL Scale: 0.82–0.89 (High reliability)
• Emotional Functioning: 0.73–0.90 (High reliability)
• Fatigue: 0.77–0.89 (High reliability)
• Pain: 0.76–0.89 (High reliability)
• Role Functioning: 0.52–0.88 (Varied, but generally acceptable)
• Physical Functioning: 0.54–0.80 (Varied, suggesting some domains are less internally consistent than others)
• Cognitive Functioning: 0.51–0.73 (Lower consistency, typical for cognitive scales)
• Social Functioning: 0.68–0.86 (Acceptable)
• Nausea/Vomiting: 0.50–0.86 (Highly variable, likely due to being a two-item scale)

These results confirm that the scales measuring global status, emotional well-being, and major symptoms (fatigue and pain) consistently demonstrate high internal consistency, making the QLQ-C30 a reliable measure for HRQoL in cancer populations.

Factor Analysis

The structure of the QLQ-C30 is fundamentally based on the results of factor analytic studies and consensus meetings among the EORTC Quality of Life Group. The initial development process utilized techniques like exploratory factor analysis to ensure that items grouped logically into distinct, interpretable scales. The final structure confirms the intended dimensionality, organizing the 30 items into 15 scales: five functional scales, three symptom scales (multi-item), six single-item symptom scales, and one global health status/QoL scale.

The functional and symptom scales are designed to be largely independent constructs, reflecting the multidimensional nature of HRQoL. Subsequent confirmatory factor analyses performed across various cultural contexts generally support this structure, validating the a priori grouping of items into the specific functional and symptom domains.

Instrument

Test Type: Self-report questionnaire, Health-Related Quality of Life (HRQoL) measure.

Format: 30 items; 28 items utilize a 4-point Likert scale (1=Not at All, 4=Very Much), and 2 items (Global QoL) utilize a 7-point Likert scale (1=Very Poor, 7=Excellent).

Language Available: Over 100 languages and dialects (maintained by the EORTC Quality of Life Group).

Population Group: Cancer patients.

Age Group: Typically adults (though pediatric versions exist separately).

Population Details: Patients undergoing various cancer treatments, particularly those participating in clinical trials where HRQoL is a primary or secondary endpoint.

Test Methodology: Patients rate their condition or experience over the past week. Scores are linearly transformed to a 0 to 100 scale. For functional scales and the global QoL scale, higher scores indicate better functioning or better QoL. For symptom scales, higher scores indicate greater severity of symptoms or problems.

Keywords

Psychometrics, Reliability, Validity, Functional Status, Symptom Burden, Global Health Status, Cancer Research, Modular Questionnaire, EORTC

Authors

Author ORCID Identifier: Not provided in source content.

Affiliation Email addresses: Not provided in source content.

Correspondence Address: Correspondence is typically managed through the EORTC Quality of Life Group.

Permissions & Fee and Test Year

The QLQ-C30 is managed by the EORTC Quality of Life Group. Use in academic research typically requires formal registration and adherence to EORTC guidelines, although the instrument is generally available at no charge for non-commercial academic research. Commercial use may incur fees. The initial core development and publication of the QLQ-C30 took place around 1988–1993. The third edition of the scoring manual was published in 2001.

The original PDF scoring manual and instrument can be accessed via the following links:

• The original PDF can be downloaded here: www.a4ebm.org/sites/default/files/Measuring%20Health.pdf
• A specimen of the QLQ-C30 (English) can be downloaded here: http://groups.eortc.be/qol/sites/default/files/img/slider/specimen_qlq-c30_english.pdf

Reference’s

The development and validation of the EORTC QLQ-C30 are supported by extensive literature, including:

• Aaronson‚ N.K.(1988). Quantitative issues in health-related quality of life assessment. Health Policy‚ 10:217–230.
• Aaronson‚ N.K.‚ Bullinger‚ M.‚ Ahmedzai‚ S. A. (1988). modular approach to quality-of-life assessment in cancer clinical trials. Recent Results Cancer Res‚ 111:231–249.
• Aaronson‚ N.K.‚ Bullinger‚ M.‚ Ahmedzai‚ S. A.‚ et al. (1988). The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology. Jnl of National Cancer Institute‚ 85(5): 365-376.
• Sprangers MAG‚ Cull‚ A.‚ Bjordal‚ K.‚ et al. (1993). The European Organization for Research and Treatment of Cancer approach to quality of life assessment: guidelines for developing questionnaire modules. Qual Life Res‚ 2:287–295.
• Aaronson‚ N.K.‚ Cull‚ A.‚ Kaasa‚ S.‚ et al. (1994). The EORTC modular approach to quality of life assessment in oncology. Int J Mental Health‚ 23:75–96.
• Montazeri‚ A.‚ Harirchi‚ I.‚ Vahdani‚ M.‚ et al. (1999). The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQC30): translation and validation study of the Iranian version. Support Care Cancer‚ 7(6):400-6
• Fayers‚ P.M‚ Aaronson‚ N.K.‚ Bjordal‚ K.‚ et al. (2001). The EORTC QLQ-C30 scoring manual. 3rd ed. Brussels: European Organisation for Research and Treatment of Cancer.
• McDowell‚ Ian. (2006). Measuring Health: A Guide to Rating Scales and Questionnaires‚ Third Edition. OXFORD UNIVERSITY PRESS
• Safaee. A.‚ Dehkordi‚ B.M. (2007). Validation Study of a Quality of Life (QOL) questionnaire for use in Iran. Asian Pac J Cancer Prev‚ 8:543-6.
• Safaee‚ A.‚ Zeighami‚ B.‚ Tabatabaee‚ H.R.‚ MoghimiDehkordi‚ B. (2008). Quality of life and Related Factors in Breast Cancer Patients under Chemotherapy. Iranian Journal of Epidemiology‚ 3(4):61-6.

Items of the EORTC Quality of Life Questionnaire QLQ-C30

IMPORTANT: The following scale items must be preserved in their original language and must not be changed in any way.